Unknown

Dataset Information

0

Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.

ABSTRACT:

SUBMITTER: Vazquez R 

PROVIDER: S-EPMC7979724 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.
| S-EPMC4996934 | biostudies-literature
Unknown Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
| S-EPMC5508733 | biostudies-literature
Unknown Clonal dynamics of native haematopoiesis.
| S-EPMC4408613 | biostudies-literature
Unknown Germline risk of clonal haematopoiesis.
| S-EPMC8117131 | biostudies-literature
Unknown Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
| S-EPMC7784272 | biostudies-literature
Unknown Venetoclax for AML: changing the treatment paradigm.
| S-EPMC6929394 | biostudies-literature
Unknown Clonal analysis of lineage fate in native haematopoiesis.
| S-EPMC5884107 | biostudies-literature
Transcriptomics Effect of venetoclax, tedizolid, and combination treatment on gene expression in a venetoclax-resistant AML cell line
2019-08-20 | GSE136032 | GEO
Unknown Recent advances in understanding clonal haematopoiesis in aplastic anaemia.
| S-EPMC5435524 | biostudies-literature
Unknown Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations.
| S-EPMC6054542 | biostudies-literature